Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The company reported a “somewhat weaker” sales performance in Q4 with the collaboration revenue of Zurzuvae being $11.4M, the analyst tells investors in a research note. The firm says shipments outpace revenues though the Zurzuvae launch doesn’t keep pace with the prior trajectory.